BMS-986020

Ligand id: 9498

Name: BMS-986020

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 101.66
Molecular weight 482.18
XLogP 9.24
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
BMS-986020 has completed Phase 2 clinical trial for treating idiopathic pulmonary fibrosis (see NCT01766817). This compound was granted Orphan Drug designation by the FDA in 2011 for treatment of idiopathic pulmonary fibrosis (link to FDA Orphan Drug Approval record here).
Mechanism Of Action and Pharmacodynamic Effects
Activation of the LPA1 receptor by LPA has been implicated in a number of disease processes, including tissue fibrosis. LPA1 receptor antagonists have displayed efficacy in a wide range of preclinical fibrosis models, including lung, skin, eye, liver and kidney.